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Aims To assess medication use in adult congenital heart disease (ACHD) patients compared to the age- and sex-
matched general population, identify patterns of pharmacotherapy, and analyse associations between pharmaco-




Data of 14 138 ACHD patients from the CONCOR registry [35 (24–48) years, 49% male] and age- and sex-
matched referents (1:10 ratio) were extracted from the Dutch Dispensed Drug Register for the years 2006–14.
Adult congenital heart disease patients had more cardiovascular and non-cardiovascular drugs than referents (me-
dian 3 vs. 1, P< 0.001). Polypharmacy, defined as >_5 dispensed drug types yearly, was present in 30% of ACHD
and 15% of referents fodds ratio [OR] = 2.47 [95% confidence interval (CI) 2.39–2.54]g. Polypharmacy was inde-
pendently associated with female sex [OR = 1.92 (95% CI 1.88–1.96)], older age [for men: OR = 2.3/10 years (95%
CI 2.2–2.4) and for women: OR = 1.6/10 years (95% CI 1.5–1.6); Pinteraction < 0.001], and ACHD severity [mild:
OR = 2.51 (95% CI 2.40–2.61), moderate: OR = 3.22 (95% CI 3.06–3.40), severe: OR = 4.87 (95% CI 4.41–5.38)].
Cluster analysis identified three subgroups with distinct medication patterns; a low medication use group (8-year cu-
mulative survival: 98%), and a cardiovascular and comorbidity group with lower survival (92% and 95%, respectively).
Cox regression revealed a strong association between polypharmacy and mortality [hazard ratio (HR) = 3.94 (95%
CI 3.22–4.81)], corrected for age, sex, and defect severity. Polypharmacy also increased the risk of hospitalization
for adverse drug events [HR = 4.58 (95% CI 2.04–10.29)].
...................................................................................................................................................................................................
Conclusion Both cardiovascular and non-cardiovascular medication use is high in ACHD with twice as much polypharmacy
compared with the matched general population. Patients with polypharmacy had a four-fold increased risk of mor-
tality and adverse drug events. Recognition of distinct medication patterns can help identify patients at highest risk.
Drug regimens need repeating evaluation to assess the appropriateness of all prescriptions. More high-quality stud-
ies are needed to improve ACHD care with more evidence-based pharmacotherapy.
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Introduction
The adult congenital heart disease (ACHD) population is still growing
and aging.1,2 Healthcare utilization is high, and drugs are more often
prescribed in ACHD than in controls.3,4 Unlike other cardiovascular
areas, evidence for drug therapy in ACHD is based on scarce clinical
data and remains mostly empiric.5 Whether current pharmacological
practice is efficient and safe in the long-term therefore remains ques-
tionable, but needs to be elucidated as drug therapy is increasingly
used to address late complications. Pharmacological treatment in
ACHD may start at a young age and may cumulate into chronic use
of multiple medications. In elderly, it is known that the concurrent
use of multiple medications, polypharmacy, is common (50%)6 and
it is generally accepted that increased drug therapy is associated with
adverse outcomes, such as adverse drug events (ADEs), hospitaliza-
tions, and death.7 However, data on polypharmacy in ACHD are
lacking. Therefore, this study assessed medication use and polyphar-
macy in ACHD in comparison to the age- and sex-matched general
population. Furthermore, we aimed to identify patterns of medica-
tion use in ACHD and to analyse the association between polyphar-
macy and adverse outcomes in ACHD.
Methods
Study population and data collection
This cohort study linked data of patients from the CONCOR registry,8
which includes adults (>_18 years) with congenital heart disease (CHD),
to the national Dispensed Drug Register (DDR) of Statistics Netherlands
(www.cbs.nl). For all Dutch residents, the DDR contains all dispensed
outpatient drugs reimbursed by the compulsory basic Dutch health insur-
ance. Drugs are classified following the Anatomical Therapeutic Chemical
(ATC) classification (Supplementary material online, Table S1), which
classifies drugs at five levels according to the organ/system on which they
act (1st) and their therapeutic (2nd), pharmacological (3rd), and chemical
properties (4th and 5th level).9 In the DDR, drugs are aggregated per per-
son per year at the 3rd level of the ATC classification. Thus, specific drugs
and their duration, timing, and daily doses within this 1-year window can-
not be extracted. Receiving a specific drug is coded as dichotomous value
for a full year, regardless of the amount of drugs dispensed. We, there-
fore, defined polypharmacy using the cumulative concept10 as >_5 differ-
ent drug types per calendar year, at the therapeutic (2nd) level of the
ATC classification, to correct for changes in pharmacological classes.
Patients were matched with randomly selected age- and sex-matched
reference subjects from the general population (1:10 ratio) to gain insight
in the increase in medication use in ACHD compared to normal for these
generally young persons (for details, see Supplementary material online,
Methods and Figure S1). Subjects were followed from 2006 or
CONCOR-inclusion until 2014 or death, using survival data from the na-
tional Cause of Death Register (CDR), which includes International
Classification of Diseases (ICD) 10th revision coded causes of all deaths
in Dutch citizens. From CONCOR, we obtained date of birth, inclusion
date, sex, and main CHD, classified into mild, moderate, and severe CHD
according to a much used consensus-based classification where proposed
level of care and survival prospects differ per severity (Supplementary
material online, Table S2).11,12
Additionally, data on hospitalizations for ADEs were collected via the
Dutch Hospital Discharge Register (HDR) for the years 2006–12. The
HDR contains person-linked discharge records of Dutch hospital admis-
sions, including ICD-9 coded diagnoses and dates of admission. We
defined hospitalizations for ADEs as admissions with ICD-9 codes 960–
979 (poisoning by drugs, medicinal, and biological substances) as main
diagnosis. The CDR was subsequently reviewed for ADEs as cause of
death in all patients (ICD-10 codes T36–T50).
CONCOR was approved by the ethics boards of all participating
centres8 and complies with the declaration of Helsinki.
Statistical analysis
Statistical analyses were performed using RStudio V.1.0.153 (RStudio
Team, Boston, MA, USA) and SPSS V.22 (IBM, Armonk, NY, USA). Data
are summarized as n (%), mean ± standard deviation, and median [inter-
quartile range (IQR)]. Two-sided P-values of <0.05 were considered stat-
istically significant.
Drug use was described as percentage of years with dispensed drugs
during the studied period. Generalized estimating equations with ex-
changeable working correlation and robust variance estimators were
used to calculate odds ratios (ORs) for specific drugs and polypharmacy
during the study in patients vs. matched referents, to determine whether
sex, age, and CHD severity were independently associated with the pres-
ence of polypharmacy, and to plot predicted probability of polypharmacy
by age in subsets per CHD severity. We performed subgroup analyses
based on CHD type, sex, and age. A sensitivity analysis excluding sex hor-
mones was performed to analyse the influence of oral contraceptives on
the difference in polypharmacy between the sexes. We also performed
sensitivity analysis excluding non-chronic drug types (including antibiotics,
full list in Supplementary material online, Table S3) to test whether the cu-
mulative definition of polypharmacy represented concurrent and con-
tinuous medication well.
To identify subgroups of patients with distinct patterns of medication
relating to diseases of different organ systems, we used an unbiased ma-
chine learning approach. Of each patient, we determined whether drugs
of the different anatomical classes of the ATC classification (1st level,
Supplementary material online, Table S1) were used at year of inclusion.
Hierarchical clustering was performed with the hclust and heatmap func-
tions in R, using binary distance to calculate the dissimilarity matrix. The
optimal number of clusters was estimated by maximizing the gap statistic
using the gap method.13 Differences between clusters were compared
using the v2 and analysis of variance tests. Survival was assessed using the
Kaplan–Meier analysis and compared between clusters using Cox hazard
regression, adjusted for age, sex, and CHD severity.
For survival analyses, we excluded patients who were included in 2014
or died in their year of inclusion, because the yearly aggregated data
required follow-up starting the following year. Cumulative survival for
patients with and without polypharmacy at inclusion was assessed per
CHD using the Kaplan–Meier curves. Associations between polyphar-
macy and all-cause mortality were analysed using multivariable Cox re-
gression adjusted for age, sex, and CHD severity, with polypharmacy as
time-varying factor. Interaction terms were used to analyse differences













































between CHD severities, and between ACHD patients and referents.
Similarly, Cox hazards regression was used to analyse whether polyphar-
macy was associated with hospitalizations for ADEs in ACHD patients.
Results
In total, 14 138 ACHD patients [age 35 (24–48) years, 49% male,
34% moderate, and 9% severe CHD] were followed for 8 (5–9) years
(baseline characteristics in Supplementary material online, Table S4).
Overall, 96 835 person-years of patients and 982 563 person-years
of referents were analysed.
Common drugs
Table 1 shows the most commonly dispensed drugs. Adult congenital
heart disease patients had higher use of cardiovascular drugs than
referents, with highest use of antithrombotics f27 vs. 6% in referents,
OR = 5.83 [95% confidence interval (CI) 5.60–6.07]g, b-blockers [24
vs. 6%, OR = 4.43 (95% CI 4.26–4.61)], and renin–angiotensin–aldos-
terone system (RAAS) inhibitors [21 vs. 7%, OR = 3.32 (95% CI
3.17–3.47)] (Table 1A).
Remarkably, most non-cardiovascular drugs were also used more
frequently in ACHD, especially systemic antibiotics [38 vs. 20%,
OR = 2.45 (95% CI 2.40–2.51)], drugs for acid-related disorders [15
vs. 10%, OR = 1.60 (95% CI 1.54–1.66)] and drugs for obstructive
airway disease [10 vs. 7% OR = 1.57 (95% CI 1.50–1.65)] (Table 1B).
Patients more commonly used drugs for thyroid disease than refer-
ents [3.8 vs. 2.0%, OR = 1.83 (95% CI 1.66–2.01)], especially patients
with complete atrioventricular septal defects [OR = 15.69 (95% CI
9.53–25.83)] who often had Down syndrome [142 of 214 patients
(67%)]. Antiepileptics also were more common [2.8 vs. 1.5%,
OR = 1.84 (95% CI 1.68–2.02)], particularly in patients with transpos-
ition of the great arteries [OR = 4.58 (95% CI 2.87–7.33)] or a func-
tionally univentricular heart [UVH; OR = 4.52 (95% CI 2.21–9.22)].
Polypharmacy
Adult congenital heart disease patients had a median of three differ-
ent dispensed drugs at year of inclusion compared to a median of one
in reference subjects (P< 0.001) (Figure 1). Twice as little patients
were free of dispensed drugs at inclusion compared to referents (17
vs. 40%, P< 0.001) (most common drugs in polypharmacy:
Supplementary material online, Table S5).
....................................................................................................................................................................................................................









Antithromboticsa (e.g. vitamin K antagonists, NOACs, platelet aggrega-
tion inhibitors)
26.5 5.4 5.83 (5.60–6.07)
b-blockersa 23.7 6.3 4.43 (4.26–4.61)
RAAS inhibitorsa 21.2 6.9 3.32 (3.17–3.47)
Diureticsa 11.4 3.8 3.23 (3.07–3.40)
Lipid modifiersa (e.g. statins) 10.3 6.7 1.48 (1.39–1.56)
Calcium channel blockersa 6.1 2.6 2.17 (2.03–2.33)
Antiarrhythmicsa 5.8 0.4 12.30 (11.23–13.47)
Other antihypertensivesa 1.4 0.3 5.95 (5.14–6.90)
Antihaemorrhagicsa (e.g. vitamin K, coagulation factors) 1.0 0.2 6.30 (5.61–7.05)
Cardiac vasodilatorsa (e.g. nitrates) 0.3 0.2 1.72 (1.31–2.24)
B. Non-cardiovascular drugs used in >10% of ACHD
Systemic antibioticsa 37.8 19.7 2.45 (2.40–2.51)
Anti-inflammatory and antirheumatic products (e.g. NSAIDs, excluding
aspirin)
17.3 17.3 1.01 (0.98–1.03)
Drugs for acid-related disordersa (e.g. PPIs and antacids) 15.1 10.3 1.60 (1.54–1.66)
Dermatological corticosteroidsa 13.6 10.6 1.33 (1.29–1.37)
Sex hormonesa (e.g. oral hormonal contraceptives) 11.2 8.6 1.33 (1.27–1.38)
Drugs for obstructive airway diseasesa [includes inhalants (adrenergics,
corticosteroids) and systemic adrenergics]
10.3 6.9 1.57 (1.50–1.65)
Analgesicsa (e.g. opioids, aspirin) 10.2 6.7 1.58 (1.52–1.65)
Ophtalmologicalsa (topical ocular drugs) 10.2 7.5 1.40 (1.35–1.46)
Use of cardiovascular medication (A) and the most common non-cardiovascular medication (B) in ACHD patients compared with the use in matched referents from the gen-
eral population. Drugs are presented according to the therapeutic classes of the Anatomical Therapeutic Chemical classification (Supplementary material online, Table S1).
ACHD, adult congenital heart disease; NOAC, non-vitamin K antagonist oral anticoagulant; RAAS, renin–angiotensin–aldosterone system.
aSignificant at the P-value <0.001 level.





































..Mean prevalence of polypharmacy during the study was 30% in
ACHD compared to 15% in referents [OR = 2.47 (95% CI 2.39–
2.54)]. Polypharmacy was independently associated with older age,
female sex, and CHD severity [mild: OR = 2.51 (95% CI 2.40–2.61),
moderate: OR = 3.22 (95% CI 3.06–3.40), and severe: OR = 4.87
(95% CI 4.41–5.38)] (Figure 2). It was particularly present in patients
with a UVH [44%, OR = 8.54 (6.62–11.02)], with many cardiovascular
drugs indicating high-cardiac morbidity, and in patients with the
Marfan syndrome [45%, OR = 4.60 (95% CI 3.98–5.31)], with notable
use of cardiovascular drugs, ocular medication [18%, OR = 2.61 (95%
CI 2.20–3.11)], and analgesics [16%, OR = 2.55 (95% CI 2.16–3.01)],
reflecting ocular and skeletal problems (e.g. scoliosis) often seen in
these syndromic patients.
Even in mild CHD, polypharmacy was already as common in 45-
year-old female and 50-year-old male patients as in 65-year-old per-
sons from the general population (Figure 3). Already 48% of patients
with severe CHD had polypharmacy at the age of 45 years, a propor-
tion only seen for persons aged >_70 years in the general population.
Overall, polypharmacy was more common in women than
men [OR = 1.92 (95% CI 1.88–1.96)]. It was already present in
24% of female patients under 40 years (vs. 12% of female refer-
ents <40), with high use of antibiotics (41%) and sex hormones
including contraceptives (31%). Even after exclusion of sex hor-
mones, polypharmacy prevalence remained higher in women
[OR = 1.88 (95% CI 1.74–1.78)]. In men, polypharmacy was less
common at young age but showed a steep incline with age
[OR = 2.3/10 years (95% CI 2.2–2.4), for women: OR = 1.6/
10 years (95% CI 1.5–1.6); Pinteraction < 0.001]; 40% of male
patients over 40 years had polypharmacy (vs. 19% of male refer-
ents >40), with high use of antithrombotics (46%) and RAAS
inhibitors (23%). These sex- and age-specific differences were
seen both in patients and referents.
Mean prevalence of polypharmacy was still 25% in ACHD com-
pared to 12% in matched referents [OR = 2.39 (95% CI 2.32–2.48)]
when non-therapeutic and non-chronic drugs were excluded for sen-
sitivity analysis.
Figure 1 Amount of different drugs types at inclusion in adult congenital heart disease patients and matched referents.
Figure 2 Factors independently associated with polypharmacy in the entire cohort, showing odds ratios (OR) for polypharmacy during the study
period. CHD, congenital heart defect.
















..Patterns of medication use
The phenotype heat map created by hierarchical clustering of medi-
cation used in ACHD demonstrated heterogeneity among patients
(Figure 4). The use of drugs acting on the cardiovascular and blood &
blood forming organs (mainly antithrombotics) seemed to co-occur
most.
The analysis arrived at three clusters as the optimal number to re-
flect phenotypic variability (Supplementary material online, Figure S2).
Figure 3 Probability of polypharmacy for women (A) and men (B) by age, stratified for congenital heart defect severity, and compared with age-
and sex-matched referents.
Figure 4 Medication phenotype heat map of adults with congenital heart disease. Columns represent individual patients and rows represent inde-
pendent phenotypes of dispensed drugs aggregated at the anatomical level of the Anatomical Therapeutic Chemical classification. Red indicates
increased value, yellow intermediate, and blue decreased value of a drug. White columns represent 2409 patients with zero drugs.





















































..The clusters differed significantly (Supplementary material online,
Table S6). As shown in Figure 5, Cluster 1 (n= 8317) had the highest
proportion of patients with drugs acting on the cardiovascular and
blood & blood forming systems. This cardiovascular cluster was the
oldest and had most patients with severe CHD (10%) and left sided
lesions (e.g. bicuspid aortic valve: 11%). Cluster 2 (n= 3501) mainly
contained patients using anti-infectives and genito-urinary medication
(sex hormones), but relative low use of other drugs, with polyphar-
macy in only 18% of patients. This low medication use cluster con-
tained young, mainly female (70%) patients, mostly with mild defects
(61%). In Cluster 3 (n= 2320), the comorbidity cluster, many patients
used extra-cardiac medication. It had the highest proportion of
patients with polypharmacy (36%) and genetic syndromes (7%).
After 8 years of follow-up, cumulative survival was 92% in the car-
diovascular cluster, 98% in the low medication use cluster, and 95% in
the comorbidity cluster. Corrected for age, sex, and CHD severity,
survival was better for the low medication use vs. cardiovascular cluster
[hazard ratio (HR) = 0.50 (95% CI 0.37–0.78), P< 0.001], but, despite
the distinct medication patterns, did not differ between the comorbid-
ity and cardiovascular cluster [HR = 0.89 (95% CI 0.71–1.11), P= 0.31].
Polypharmacy and outcome
Survival analyses included 13 527 patients and 135 647 referents.
During 7 (5–8) years, 595 (4%) patients and 2375 (2%) referents died
(Figure 6). Eight-year mortality was higher in patients with polyphar-
macy at inclusion compared to those without polypharmacy
(Figure 7). Corrected for age, sex, and defect severity, polypharmacy
during the study was strongly associated with all-cause mortality in
ACHD [HR = 3.94 (95% CI 3.22–4.81)]. The age- and sex-adjusted
association was similar between the CHD severities (Pinteraction =
0.96 for moderate and Pinteraction = 0.70 for severe CHD compared
to mild CHD) and was significantly stronger in ACHD patients than
in referents (Pinteraction < 0.001).
A total of 10 015 ACHD patients were uniquely identified in the
HDR between 2005 and 2012. During a median of 5 (IQR 3–6) years,
21 ACHD patients were hospitalized for an ADE. Increasing drug
amounts were associated with ADEs [HR = 1.20/dispensed drug
(95% CI 1.10–1.32)]. Patients with polypharmacy were at markedly
higher risk of hospitalization for an ADE compared to patients with-
out polypharmacy [HR = 4.03 (95% CI 1.67–9.73)]. None of the
patients that died during the study had ADEs as cause of death.
Discussion
This study shows that ACHD patients not only use more cardiovas-
cular medication than the general population, but also use more
extra-cardiac drugs, cumulating into polypharmacy in 30% of the
patients compared to only 15% of referents. The study identified dis-
tinct medication patterns, which differed by age, sex, and CHD.
Furthermore, patients with polypharmacy had an almost four-fold
higher risk of all-cause mortality and almost five-fold higher risk of
hospitalizations for ADEs.
Recently, ACHD investigators have stressed the need for
more evidence regarding drug therapy in this growing population.5
Trials investigating safety and efficacy of drugs in ACHD often remain
Figure 5 Clinical characteristics and medication use at inclusion stratified by phenogroup. Numbers represent the percentage of patients per sub-
group with medication for the different organ systems used at year of inclusion.



















































..small.14,15 The existing pool of evidence in this area therefore only
grows slowly and remains largely empiric. Some epidemiologic stud-
ies have identified common drugs in ACHD cohorts.4,16 However,
this study is the first to investigate polypharmacy and its associations
with clinical characteristics and outcome in ACHD. Furthermore,
this is the largest study comparing medication use in ACHD to the
general population.
Previous studies focusing on other chronic conditions, such as dia-
betes mellitus, chronic kidney disease, and chronic heart failure, have
shown comparably high odds for polypharmacy of these diseases.17,18
Compared to these populations, ACHD patients are special due to
their young age and lifelong disease which may involve both cardiac
and extra-cardiac comorbidities. Polypharmacy in 15% of the age-
matched referents may seem high but is close to other findings using
cumulative definitions of polypharmacy during a 1-year period.19 Not
surprisingly, polypharmacy risk in our study increased with increasing
CHD severity, which involves more cardiovascular complications
requiring medical intervention.16,20
Apart from common use of cardiovascular drugs, use of many
non-cardiovascular drugs was increased in ACHD. Previous research
showed increased prevalence of drugs related to asthma and epilepsy
in patients who underwent surgery for a CHD as children.4 Especially
in patients with genetic syndromes, extra-cardiac comorbidities are
common.4,21 In our cohort, we saw increased use of a large range of
drugs, including drugs for acid-related disorders, dermatologicals, and
sex hormones. This indicates high prevalence of extra-cardiac
comorbidities in the ACHD population. Contra-indications for
pregnancy are more common in women with cardiovascular dis-
ease22 and may explain a higher preventive use of oral contraceptives
in ACHD.
Interestingly, polypharmacy was even increased in mild CHD and
at young age, reflecting decreased health even in these mildly affected
patients. Alternatively, the increase in medication use may originate
from intensive surveillance that facilitates early diagnosis and treat-
ment.3 The particularly higher prevalence of polypharmacy in female
compared to male ACHD patients at young age is in line with general
sex differences that depend on differences including prevalence of
morbidities and adverse drug effects, need for anticonceptives, and a
lower likelihood to seek preventive healthcare in men.23
Cluster analysis revealed three distinct patterns of medication use
in ACHD, described as cardiovascular, low medication use, and comor-
bidity patterns. Cluster analysis based on phenotypical data has been
used previously to identify distinct subgroups within other heteroge-
neous populations.24,25 This unbiased approach makes it possible to
identify patterns regardless of assumptions about clinical correlations.
The identification of such distinct subgroups could be used to help
target therapies and trials in heterogeneous syndromes such as
ACHD. Clinical trials are prone to select patients without marked
comorbidity, but concurrent use of different drugs is important to
identify due to increased risk of drug–drug interactions and
ADEs.26,27 This may be most crucial in the comorbidity subgroup.
This study showed, without implying causality, that patients with
polypharmacy had a four-fold higher mortality risk (HR = 3.94), inde-
pendent of age, sex, and defect severity. Furthermore, risk of
Figure 6 Kaplan–Meier survival curve of adult congenital heart disease (ACHD) patients and matched referents with and without polypharmacy at
inclusion.






























































hospitalization for adverse drug events was nearly five times higher in
patients with polypharmacy (HR = 4.58). Interestingly, polypharmacy
in the ACHD population was more associated with mortality than in
the general population. Patients with polypharmacy may be sicker
(needing therapy) than referents with polypharmacy (who e.g. often
have statins as prevention). Whether an increased amount of drugs is
an independent risk factor or a mere measure of poor health and
multimorbidity, remains to be elucidated.6,7 Polypharmacy may en-
hance risk of adverse drug events, including bleeding due to antith-
rombotics,28 and increased amounts of drugs correlate with
hospitalizations for adverse drug reactions.26,27 Notably, drugs often
prescribed in ACHD, especially anticoagulants, are among the drugs
most commonly causing ADE-related emergency department visits
and hospitalizations.29,30 Benefits of prescribing may outweigh the
risks of ADEs, but evidence of beneficial effects of many therapies in
ACHD is still limited.5 In elderly, guidelines with criteria to start and
stop certain drugs have been established to minimize inappropriate
prescribing,31 and it has been suggested that deprescribing to reduce
inappropriate polypharmacy can reduce mortality without harm.32,33
Clinical implications
The remarkably high prevalence of polypharmacy in ACHD shows
that experience with managing polypharmacy is needed in the effi-
cient management of these patients. Physicians should carefully judge
drug indications in ACHD, especially as pharmacotherapy is often
based on low-level evidence extrapolated from non-ACHD studies
or small studies involving heterogeneous ACHD patients. Long-term
use of some medication, e.g. amiodarone, may be suboptimal due to
side effects.5 Occasionally, withdrawal of longstanding therapy with
only weak indications might be an option. Trials that examine efficacy
and safety of drug therapy in ACHD are warranted, and the effects of
longstanding polypharmacy in these patients need to be studied
further to enhance guidelines on the management of this complex
population.
Methodological issues
These data from national administrative databases enable insightful
comparisons with the general population. Automated data collection
limits recall bias seen in questionnaires and data on dispensed drugs
provide more accurate information on actual drug consumption than
medical records, as these prescriptions have been filled. However,
actual drug consumption may be overestimated, as we have no data
on compliance. Non-compliance is of importance because it is associ-
ated with mortality and increases with treatment intensity and dur-
ation,34,35 although compliance in the Netherlands is reported to be
high (>80%).36
The lack of clinical detail inherent to administrative data introduces
indication bias, as no information on drug indications, comorbidities,
and functional status are available. We used the consensus-based se-
verity classification to subdivide patients with different risks.
However, mortality risk may vary within specific CHDs due to late
complications, such as pulmonary hypertension in patients with sep-
tal defects. Therefore, these data do not provide information about
individual patients, but give insight on a population level.
Furthermore, appropriateness of polypharmacy is not assessed and
associations with mortality have to be interpreted with caution, as
polypharmacy may mark high-risk patients with multimorbidity.
Other limitations inherent to the data set include unavailability of
data on over-the-counter medication, and data on treatment dur-
ation, daily doses, and specific distributed drugs. Our cumulative
measures of polypharmacy may overestimate the prevalence of
simultaneous pharmacotherapy, due to inclusion of successive and
non-chronic drugs in the observed time frame. We limited this by
aggregating drugs by therapeutic class, correcting for switches in
pharmacological class. Such cumulative definitions of polypharmacy
Figure 7 Eight-year cumulative mortality for patients with and without polypharmacy at inclusion per congenital heart defect. ASD, atrial septal de-
fect; BAV, bicuspid aortic valve; cAVSD, complete atrioventricular septal defect; CoA, coarctation of the aorta; Ebstein, Ebstein’s anomaly; LVOTO,
left ventricular outflow tract obstruction; pAVSD, partial atrioventricular septal defect; RVOTO, right ventricular outflow tract obstruction; TGA,
transposition of the great arteries; TOF, tetralogy of Fallot; UVH, univentricular heart; VSD, ventricular septal defect.


































































































are common and give comparable, clinically relevant, and as reliable
results as other measures of polypharmacy.10,19,37
Conclusion
In conclusion, ACHD patients used both more cardiovascular and
non-cardiovascular medication compared to the general population,
with polypharmacy in 30% of ACHD vs. just 15% of referents.
Polypharmacy was even common in mild CHD at young ages. We
identified different medication patterns that could be taken into ac-
count to help target therapies and trials in this heterogeneous popu-
lation. As patients with polypharmacy had a four-fold higher risk of
death and adverse drug events, daily clinical care of ACHD patients
must include regular evaluation of their medication regimen, particu-
larly in case of polypharmacy. Further clinical trials to investigate risks
and benefits of pharmacotherapy remain needed to come to more
evidence-based treatment in this population.
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Supplementary material is available at European Heart Journal –
Cardiovascular Pharmacotherapy online.
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